Exciting Expansion and Strategic Partnerships Propel Future Outlook

NeuroOne Medical Technologies Corporation has announced a stellar performance in its financial results for the fourth quarter and fiscal year ending September 30, 2024. The company’s product revenue surged by 77%, reaching $3.5 million, compared to $2.0 million in FY23, driven by strong demand and key partnerships, particularly with Zimmer Biomet.

CEO Dave Rosa shared, “Our expanded partnership with Zimmer Biomet is a major milestone. This exclusive collaboration will see Zimmer distribute our OneRF™ Ablation System for brain treatments across the U.S. and select international markets, a partnership expected to significantly boost revenue and margins in FY25.”

The company’s fiscal year 2025 outlook is optimistic, with projected product revenue set to reach between $8 million and $10 million, a remarkable year-over-year increase of 132% to 190%. Gross margins are expected to rise from 31% in FY24 to 47%–51% in FY25, reflecting the increasing demand for NeuroOne’s cutting-edge medical technologies.

NeuroOne is also making significant strides in other areas, including discussions on its OneRF™ Ablation System for peripheral pain and new developments in its trigeminal nerve ablation product, aimed at treating facial pain. With a robust product pipeline and a strategic focus on partnerships, NeuroOne is poised for continued growth and innovation in the medical technology sector.

The company ended FY24 with a net loss of $12.3 million, a slight increase from the previous year, but remains confident in its trajectory as it navigates expanding opportunities.